The DIMENSION study offered by Sage Therapeutics, Inc. is investigating SAGE-718 for the treatment of cognitive symptoms associated with Huntington disease (HD) in adults with premanifest or early manifest HD. SAGE-718 has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) in September 2021 as a potential treatment for HD. Fast Track is a process designed to facilitate the development and review of new treatments for serious conditions with unmet medical need, such as HD.
DIMENSION is a Phase 2, randomized, double-blind, placebo-controlled study. The objectives of DIMENSION are to:
- Evaluate the efficacy of SAGE-718 to reduce cognitive symptoms associated with HD
- Evaluate the safety and tolerability of SAGE-718 in subjects with HD
The study is registered at ClinicalTrials.gov.
Phase II Clinical Trial
Location: Sage Investigational Site
North York, ON M2K 1E1
|Contact: Emily Lefler, PharmD||(619) firstname.lastname@example.org|
Contact email: email@example.com
For more detailed information on this study and others and for the most recent updates, please go to clinicaltrials.gov. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.